Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 4:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 1,881 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Renal Diseases Clear all
Completed Phase 2 Interventional Results available

Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)

NCT02966028
View directory record Official record
Conditions
Cardiovascular Diseases, Cardiovascular Abnormalities, Calcifications, Vascular, Endstage Renal Disease, ESRD, Coronary Artery Calcification
Interventions
SNF472, Placebo
Drug
Lead sponsor
Sanifit Therapeutics S. A.
Other
Eligibility
18 Years to 80 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
46
States / cities
Bakersfield, California • Chula Vista, California • Escondido, California + 42 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2021 · Synced Oct 15, 2026, 4:56 PM EDT
Completed Phase 3 Interventional Results available

Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease

NCT05085275
View directory record Official record
Conditions
Anemia, Iron Deficiency, Hyperphosphatemia, Renal Insufficiency, Chronic, Renal Anemia, Disease Progression, Cardiovascular, Iron
Interventions
Ferric Citrate 1 GM Oral Tablet [AURYXIA], Placebo
Drug
Lead sponsor
USRC Kidney Research
Network
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
23
States / cities
Pine Bluff, Arkansas • Chula Vista, California • El Centro, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 15, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function

NCT02678000
View directory record Official record
Conditions
Chronic Kidney Disease (CKD)
Interventions
LHW090, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 85 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Anaheim, California • Lakewood, Colorado • Miami Lakes, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 15, 2026, 4:56 PM EDT
Withdrawn Phase 2 Interventional

Study of the Safety and Effectiveness of Rilonacept (IL-1 Trap) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Anemia

NCT00609544
View directory record Official record
Conditions
Chronic Kidney Disease, Anemia
Interventions
Rilonacept
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
27
States / cities
Alexander City, Alabama • Muscle Shoals, Alabama • Cerritos, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 15, 2026, 4:56 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

NCT01931644
View directory record Official record
Conditions
All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
17,667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 15, 2026, 4:56 PM EDT
Completed Not applicable Interventional

The Effect of Dietary Nitrates on Physical Performance and Vascular Function in Chronic Kidney Disease

NCT04103736
View directory record Official record
Conditions
Kidney Disease, Chronic, Endothelial Dysfunction
Interventions
Beet It Sport Shot, Nitrate-depleted placebo
Dietary Supplement
Lead sponsor
University of Delaware
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 15, 2026, 4:56 PM EDT
Completed Phase 2 Interventional

A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

NCT05536804
View directory record Official record
Conditions
Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
10
States / cities
Northridge, California • Aurora, Colorado • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 15, 2026, 4:56 PM EDT
Completed Not applicable Interventional

Pilot Study of Health Information Technology for Chronic Kidney Disease Management

NCT02990897
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
clinical decision support message
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Danvers, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Oct 15, 2026, 4:56 PM EDT
Completed No phase listed Observational

Effect of SGLT2i on Cardiovascular Biomarkers in Patients With Type 2 Diabetes and CKD Stage 3b-4

NCT05033054
View directory record Official record
Conditions
Kidney Disease, Chronic, Diabetes
Interventions
SGLT2 inhibitor
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 15, 2026, 4:56 PM EDT
Completed Not applicable Interventional

Reduction of Mortality Prior to and During the First 90 Days of Dialysis Through a Renal Rehabilitation Program

NCT00792454
View directory record Official record
Conditions
Chronic Kidney Disease, End Stage Kidney Disease, Cardiovascular Disease
Interventions
exercise training
Behavioral
Lead sponsor
MaineHealth
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 15, 2026, 4:56 PM EDT
Enrolling by invitation No phase listed Observational

System Interventions to Achieve Early and Equitable Transplants Study - Long-Term

NCT07515794
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 15, 2026, 4:56 PM EDT
Completed Not applicable Interventional Results available

A Culturally Sensitive Values-Guided Aid for End of Life Decision-Making

NCT00122135
View directory record Official record
Conditions
Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Cirrhosis, Colon Carcinoma, Lung Cancer, Chronic Kidney Disease
Interventions
Values Inventory (VI)
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
55 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 15, 2026, 4:56 PM EDT
Terminated Not applicable Interventional Results available

Using Intradialytic Blood Pressure Slopes to Guide Ultrafiltration

NCT03303391
View directory record Official record
Conditions
ESRD, Extracellular Fluid Alteration, Hypertension
Interventions
Intradialytic Blood Pressure Slope Based Ultrafiltration
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Oct 15, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

A Study in Participants With End-Stage Renal Disease

NCT01200290
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
LY2127399
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 15, 2026, 4:56 PM EDT
Terminated Phase 3 Interventional Results available

Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy

NCT00108485
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Kidney Failure, Chronic, Hyperlipidemia
Interventions
Extended release niacin, Placebo
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Oct 15, 2026, 4:56 PM EDT
Terminated Not applicable Interventional Results available

Effect of Harvoni on Proteinuria and eGFR in Hepatitis C Virus Associated Chronic Kidney Disease (CKD)

NCT02503735
View directory record Official record
Conditions
Hepatitis C, Chronic Kidney Disease
Interventions
Sofosbuvir/Ledipasvir FDC
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 15, 2026, 4:56 PM EDT
Completed No phase listed Observational

Biorepository of Biospecimen Samples in Matched Healthy Control Participants and Participants Diagnosed With Diabetic Kidney Disease, Chronic Kidney Disease, or Type 2 Diabetes

NCT05631119
View directory record Official record
Conditions
Diabetic Kidney Disease, Diabetes Type 2, Chronic Kidney Diseases, Healthy
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Timeline
2022 – 2023
U.S. locations
1
States / cities
Woburn, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 15, 2026, 4:56 PM EDT
Terminated Not applicable Interventional Results available

Effects of Ergocalciferol on Erythropoetin Stimulating Agent Dose

NCT01263028
View directory record Official record
Conditions
Chronic Kidney Disease Stages 3-5
Interventions
Ergocalciferol supplementation
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Oct 15, 2026, 4:56 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

StatStrip A Glucose/Creatinine Meter System Lay User Study Evaluation

NCT05144971
View directory record Official record
Conditions
Diabete Mellitus, CKD, ESRD
Interventions
Glucose, Creatinine
Diagnostic Test
Lead sponsor
Nova Biomedical
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Miami Gardens, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 15, 2026, 4:56 PM EDT
Terminated Phase 3 Interventional Results available

Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidney Disease

NCT01012414
View directory record Official record
Conditions
Coronary Artery Disease, Chronic Kidney Disease, Hypovitaminosis D, Secondary Hyperparathyroidism
Interventions
paricalcitol, placebo
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 15, 2026, 4:56 PM EDT
Completed Not applicable Interventional Results available

Kidney Coordinated Health Management Partnership

NCT03832595
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
EHR-based PHM, Usual Care
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 85 Years
Enrollment
1,596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 15, 2026, 4:56 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

NCT07107945
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
2 Years to 17 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
25
States / cities
Birmingham, Alabama • Palo Alto, California • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 15, 2026, 4:56 PM EDT
Not yet recruiting No phase listed Observational

Refining Risk Prediction Models for Older Adults Using Electronic Health Records

NCT06995365
View directory record Official record
Conditions
Predictive Modeling
Interventions
Risk Prediction Model
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
65 Years and older
Enrollment
18,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 15, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)

NCT03457701
View directory record Official record
Conditions
Anaemia
Interventions
Daprodustat, rhEPO, Ferrous sulfate containing the stable iron isotope (57Fe), Ferrous sulfate containing the stable iron isotope (58Fe)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Fort Worth, Texas • Lufkin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 15, 2026, 4:56 PM EDT